One Postdoc position (Norwegian Cancer Society) is available for a period of three years, from June 2016. This is a shared position at the Section for Cancer Immunology/IKF (Smeland/Myklebust) and Section for Cellular Therapy /KKT (Kvalheim), Radiumhospitalet-OUS.
The Section for Cellular therapy is home to one of Europe’s biggest and most modern GMP facilities for cellular products and also provides cellular products for industry trials abroad. The section counts 35 employees and the research focus of the translational research team at the section is the development of new immunotherapy treatments for cancer. This includes the pre-clinical and clinical development and testing of improved cancer vaccines and adoptive T cell therapy.